In late December, Egalet submitted an NDA for its Arymo ER abusedeterrent (AD) morphine tablet – a widely prescribed opiate with few AD competitors. Management expects to complete clinical trials in early 2017 to support a mid 2017 NDA filing for its AD oxycodone tablet. If approved, this will open Egalet to the $2.5bn market for oxycontin with a proprietary AD formulation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Innovating abuse deterrent drugs
- Published:
01 Apr 2016 -
Author:
Beth Senko -
Pages:
2
In late December, Egalet submitted an NDA for its Arymo ER abusedeterrent (AD) morphine tablet – a widely prescribed opiate with few AD competitors. Management expects to complete clinical trials in early 2017 to support a mid 2017 NDA filing for its AD oxycodone tablet. If approved, this will open Egalet to the $2.5bn market for oxycontin with a proprietary AD formulation.